Determined by the subgroup Evaluation, we found that there was significant heterogeneity in terms of mortality, favorable outcomes, and the total treatment method powerful charge. Regarding mortality, The explanation for heterogeneity on the subgroup of edaravone dexborneol and EDV was predominantly attributed to dissimilarities in drug dosage. Concerning favorable results, https://neuroprotectives-for-sale69135.madmouseblog.com/13791531/the-definitive-guide-to-buy-neuroprotectives-online